Brain antioxidant activities of six artemisinin-based combination therapies (acts) in experimental malaria model
Table Of Contents
Chapter ONE
INTRODUCTION
- 1.1Introduction
- 1.2Background of Study
- 1.3Problem Statement
- 1.4Objective of Study
- 1.5Limitation of Study
- 1.6Scope of Study
- 1.7Significance of Study
- 1.8Structure of the Research
- 1.9Definition of Terms
Chapter TWO
LITERATURE REVIEW
- 2.1Overview of Antioxidants
- 2.2Artemisinin-Based Combination Therapies (ACTs)
- 2.3Malaria as a Global Health Issue
- 2.4Previous Studies on Antioxidant Activities
- 2.5Mechanisms of Antioxidant Action
- 2.6Efficacy of ACTs in Malaria Treatment
- 2.7Side Effects of ACTs
- 2.8Interactions with Other Antioxidants
- 2.9Pharmacokinetics of ACTs
- 2.10Future Trends in Antioxidant Research
Chapter THREE
RESEARCH METHODOLOGY
- 3.1Research Design
- 3.2Sampling Techniques
- 3.3Data Collection Methods
- 3.4Data Analysis Procedures
- 3.5Ethical Considerations
- 3.6Validity and Reliability
- 3.7Research Limitations
- 3.8Research Assumptions
Chapter FOUR
DATA PRESENTATION AND ANALYSIS
- 4.1Overview of Findings
- 4.2Antioxidant Activities of ACT A
- 4.3Antioxidant Activities of ACT B
- 4.4Antioxidant Activities of ACT C
- 4.5Antioxidant Activities of ACT D
- 4.6Antioxidant Activities of ACT E
- 4.7Antioxidant Activities of ACT F
- 4.8Comparison of Antioxidant Potency
Chapter FIVE
SUMMARY, CONCLUSION AND RECOMMENDATIONS
- 5.1Summary of Findings
- 5.2Conclusion
- 5.3Recommendations for Future Research
- 5.4Implications for Clinical Practice
- 5.5Contribution to Existing Knowledge
Project Abstract
<p> </p><p>Malaria parasite has remained a menace to human immune system as it usually subjects its host to oxidative stress which in turn has an effect on the levels of the antioxidant system due to generation of reactive oxygen species. This study investigated the brain antioxidant activities with six artemisinin-based combination therapies in an experimental malaria model. Forty (40) adult male Swiss albino mice between 20 – 30 g were randomized into 8 groups of 5 animals each. Groups 1 served as the normal control (NC) and were given normal feed and distilled water. Group 2positive control (PC) received 0.2ml of parasitized erythrocyte from a donor mouse. Group 3 was treated with 5.71 mg/kg body weight (ml/kg bw) Artesunate-amodiaquine – AA (CAMOSUNATE®) for 3 days, group 4 received 6.43 mg/kg bw Artesunate-mefloquine – AM (Artequin™) for 3 days, group 5 were given 2.86 mg/kgbw Artesunate-sulfadoxine-pyrimesthamine – ASP (SIMBCURE®) for 3 days, group 6 received 12.5 mg/kg bw Artemisinin-piperaquine – AP(ARTEQUICK®) for 2 days, group 7 received 5.14 mg/kg bw Dihydroartemisinin-piperaquine – DP (P-ALAXIN™) and group 8 received 8 mg/kg bw Artemether-lumefantrine – AL (Coartem®) for 3 days through oral administration after being inoculated with <em>Plasmodium berghei</em> strain intraperitoneally. The mice were then sacrificed by chloroform inhalation after treatment. The mice brain was harvested and the brain homogenates were used for antioxidant assay, also blood sample was obtained through cardiac puncture for parasite estimation. Result for parasitaemia level showed a significant decreased in groups 3, 4, 6, 7 and 8 in order of decreasing efficacy; AM > DP > AP > AA > AL > ASP. Implying the all the ACTs except ASP were efficacious in parasite clearance. AA, AM, AL and ASP groups had significant depleted levels of GSH, SOD, GPx and GST whereas CAT, MDA levels significantly increased with ASP, AP and DP when compared with NC groups. The vitamins showed variant results with the drugs as there were decreased levels of vitamin C in AP and DP groups while all the artesunate combinations elevated the levels of vitamins E and A. In conclusion the ACTs used suppressed the expression of most of the brain antioxidants even after parasite clearance, possibly due early onset of mice recovery from infection.</p><p><strong>Keywords;</strong> Antioxidants, Artemisinin-based combination therapy, Brain, Malaria.</p> <br><p></p>
Project Overview